Earnings are a measure of the money a company is making. That is the reason why companies’ earnings growth captivates almost everyone, from the top brass to research analysts.Still, earnings acceleration works even better when lifting the stock price. Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in their price.Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-ove ...

Shares of Evolus, Inc. (EOLS) have gained 5% over the past four weeks to close the last trading session at $14.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $23 indicates a potential upside of 63.2%.The mean estimate comprises six short-term price targets with a standard deviation of $3.85. While the lowest estimate of $16 indicates a 13.6% increase from the current price ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gross proceeds from the offering to Evolus are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and offering expenses. In additio ...

Dr. Rui Avelar, MD Chief Medical Officer and H e a d of R&D DISCLOSURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals rela ...

Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Louise Chen - Cantor Fitzgerald Navann Ty - BNP Paribas Serge Belanger - Needham & Company Uy Ear - Mizuho Securities Douglas Tsao - H.C. Wainwright Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________ FORM 10-K _____________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38381 _____________________________ EVOLUS, INC. (Exact name of registrant as speci ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET. Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025. The filler line will be branded Evolysse™ in the US and Estyme® in the UK and Europe. The Evolys ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conferences in March. Event: The Leerink Partners Global Biopharma Conference 2024 Date: Tuesday, March 12th, 2024 Time: 10:00-10:30am ET Event: The Barclays 26th Annual Global Healthcare Conference Date: Wednesday, March 13th, 2024 Time: 8:00-8:25am ET The fireside ch ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will ...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 15,101 restricted stock units (RSUs) of the company’s common stock to 7 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under Evolus’ 2023 Inducement Incentive Plan, with a grant date and a vesting commencem ...